Madrigal Pharmaceuticals Bolsa (NASDAQ: MDGL)

Últimas noticias sobre Madrigal Pharmaceuticals (NASDAQ:MDGL) Bolsa

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals Inc

Wells Fargo analyst Ike Boruchow maintains Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) with a Equal-Weight and lowers the price target from $215 to $210.

News

Price Target

Analyst Ratings

DECK

Wells Fargo Maintains Equal-Weight on Deckers Outdoor, Lowers Price Target to $210

Scotiabank analyst Greg Harrison maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform and raises the price target from $430 to $433.

VRTX

Scotiabank Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $433

Guidance

Exxon Mobil CEO Darren Woods Says Yellowtail Project In Guyana Could Start By Q3 2025; Says Major Planned Projects For 2025 Could Begin Ahead Of Schedule

Scotiabank analyst Nick Altmann maintains Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) with a Sector Perform and raises the price target from $250 to $330.

TEAM

Scotiabank Maintains Sector Perform on Atlassian, Raises Price Target to $330

Scotiabank analyst Cameron Bean maintains Spartan Delta (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SDE#TSX">SDE</a>) with a Sector Outperform and raises the price target from C$6 to C$7.5.

TSX:SDE

Scotiabank Maintains Sector Outperform on Spartan Delta, Raises Price Target to C$7.5

Macro Economic Events

Economics

CORRECTION: Chicago PMI For Jan. 39.5 Vs 40.3 Est.; 36.9 Prior

Looking into the current session, Simon Property Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPG#NYSE">SPG</a>) shares are trading at $175.53, after a 0.15% drop. Over the past month, the stock fell by 0.05%, but over the past year, it actually increased by 28.65%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1738334832_0.png" alt="Past Year Chart" />

<h3>A Look at Simon Property Group P/E Relative to Its Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Simon Property Group has a lower P/E than the aggregate P/E of 71.93 of the Retail REITs industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1738334832_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

Price Over Earnings Overview: Simon Property Group

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 150 points on Friday.
Following the market opening Friday, the Dow traded up 0.19% to 44,968.22 while the NASDAQ climbed 0.84% to 19,847.18. The S&amp;P 500 also rose, gaining, 0.41% to 6,095.78.
Check This Out: <a href="https://www.benzinga.com/25/01/43388778/jim-cramer-autozone-is-a-great-stock-recommends-buying-this-energy-stock">Jim Cramer: AutoZone Is A &#8216;Great&#8217; Stock, Recommends Buying This Energy Stock</a>
Leading and Lagging Sectors Communication services shares surged by 0.8% on Friday.
In trading on Friday, energy shares fell by 1.4%.
Top Headline
Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) reported better-than-expected first-quarter financial results after the market close on Thursday.
Apple reported fiscal first-quarter revenue of $124.3 billion, beating analyst estimates of $124.13 billion. The iPhone maker reported first-quarter adjusted earnings of $2.40 per share, beating analyst estimates of $2.36 per share. However, sales of its iPhone handset device declined to $69.14 billion from $69.70 billion in the year-ago period.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>TCTM Kids IT Education Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCTM#NASDAQ">TCTM</a>) shares shot up 187% to $0.5197.</li>
<li>Shares of Signing Day Sports, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGN#NYSE">SGN</a>)got a boost, surging 70% to $4.34 after the company announced it retains rights as the National Recruiting Partner to the U.S. Army Bowl through 2026 in new deal.</li>
<li>NLS Pharmaceutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NLSP#NASDAQ">NLSP</a>) shares were also up, gaining 45% to $2.85 after announcing its merger with Kadimastem has been approved by shareholders.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Enveric Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) shares dropped 45% to $2.16 after the company announced a $5 million public offering of 1.67 million units of common stock.</li>
<li>Shares of NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) were down 40% to $0.1554 after the company announced a 1-for-20 reverse stock split.</li>
<li>Benson Hill, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHIL#NASDAQ">BHIL</a>) was down, falling 34% to $2.62. Benson Hill recently announced results from a controlled broiler feeding trial conducted with Tyson Foods.</li>
</ul>
Commodities In commodity news, oil traded up 0.1% to $72.76 while gold traded up 0.2% at $2,850.80.
Silver traded up 0.5% to $32.64 on Friday, while copper fell 1% to $4.2665.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.3%, Germany's DAX 40 gained 0.2% and France's CAC 40 climbed 0.3%. Spain's IBEX 35 Index fell 0.1%, while London's FTSE 100 rose 0.4%.
Asia Pacific Markets
Asian markets closed higher on Friday, with Japan's Nikkei 225 gaining 0.15% and India's BSE Sensex gaining 0.97%.
Economics
<ul>
<li>U.S. personal income increased 0.4% month-over-month in December compared to a 0.3% gain in November.</li>
<li>Personal spending climbed by 0.7% month-over-month to an annualized rate of $20.387 trillion in December.</li>
<li>The core PCE price index in the US increased by 0.2% from the previous month for December.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43390127/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Trading Ideas

AAPL

BHIL

ENVB

NIVF

NLSP

TCTM

Nasdaq Jumps Over 150 Points; Apple Posts Upbeat Earnings

Boot Barn Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) has outperformed the market over the past 10 years by 9.23% on an annualized basis producing an average annual return of 20.65%. Currently, Boot Barn Holdings has a market capitalization of $4.77 billion. 
Buying $100 In BOOT: If an investor had bought $100 of BOOT stock 10 years ago, it would be worth $719.37 today based on a price of $156.39 for BOOT at the time of writing.
<h3>Boot Barn Holdings's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738334709_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BOOT

Here's How Much You Would Have Made Owning Boot Barn Holdings Stock In The Last 10 Years

Tembo operates across international markets, including Asia, the Middle East, Africa, Oceania, Europe and North America&nbsp;
Increasing adoption of digital assets and currencies across these markets enables Tembo to provide these payment options, with potential benefits to its working capital cycle
LONDON, Jan. 31, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVPR#NASDAQ">VVPR</a>) ("VivoPower" or the "Company") announced today that its subsidiary, Tembo e-LV will commence accepting payments for deposits and orders in Bitcoin (BTC), Ripple (XRP), and Dogecoin (DOGE).

$BTC

$DOGE

$XRP

VVPR

VivoPower's Tembo To Accept Bitcoin, Ripple, And Dogecoin For Payments From Customers And Partners

Canada PM Trudeau Says If Trump Does Choose To Implement Any Tariffs Against Canada, We're Ready With A Response, Says Any Canadian Response To Tariffs Would Be Purposeful, Forceful And Immediate; Says If We Have To Act We Wouldn't Relent Until Tariffs Are Removed, Adds Everything Is On The Table

Susquehanna analyst James Friedman maintains Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) with a Positive and raises the price target from $375 to $395.

Susquehanna Maintains Positive on Visa, Raises Price Target to $395

Scotiabank analyst Maher Yaghi maintains Rogers Communications (TSX:<a class="ticker" href="https://www.benzinga.com/stock/RCI#TSX">RCI</a>) with a Sector Outperform and lowers the price target from C$64 to C$58.

TSX:RCI

TSX:RCI/B

Scotiabank Maintains Sector Outperform on Rogers Communications, Lowers Price Target to C$58

Susquehanna analyst Bascome Majors maintains United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) with a Neutral and lowers the price target from $140 to $130.

Susquehanna Maintains Neutral on United Parcel Service, Lowers Price Target to $130

ABBV

AbbVie Expects Net Revenues Of About $12.8B For Q1, Adj. Eps Between $2.47 And $2.51

Susquehanna analyst Christopher Rolland maintains STMicroelectronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) with a Positive and lowers the price target from $33 to $28.

Susquehanna Maintains Positive on STMicroelectronics, Lowers Price Target to $28

Orrstown Finl Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORRF#NASDAQ">ORRF</a>) just disclosed its Q4 earnings on Friday, January 31, 2025 at 07:22 AM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Orrstown Finl Servs missed estimated earnings by -16.0%, reporting an EPS of $0.87 versus an estimate of $1.03.
Revenue was up $24.55 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
The company beat on EPS by $0.19 in the last quarter, resulting in a 3.0% increase share price change the following day.
Here's a look at Orrstown Finl Servs's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.92</td>
<td>0.73</td>
<td>0.73</td>
<td>0.80</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.11</td>
<td>0.83</td>
<td>0.88</td>
<td>0.83</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>49.23M</td>
<td>25.97M</td>
<td>25.80M</td>
<td>26.25M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>51.70M</td>
<td>26.10M</td>
<td>26.88M</td>
<td>26.02M</td>
</tr>
</tbody>
</table>

 Listen to the earnings announcement yourself by <a href="">clicking here</a>. 
To track all earnings releases for Orrstown Finl Servs <a href="https://www.benzinga.com/quote/ORRF/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ORRF

Earnings Breakdown: Orrstown Finl Servs Q4

Susquehanna analyst Bascome Majors maintains Schneider National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) with a Neutral and raises the price target from $31 to $32.

SNDR

Susquehanna Maintains Neutral on Schneider National, Raises Price Target to $32

AbbVie Exec Says Co Expects Humira Revenue Of $5.6B, With US Sales Of $4B In 2025

Susquehanna analyst James Friedman maintains Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) with a Positive and raises the price target from $605 to $670.

Susquehanna Maintains Positive on Mastercard, Raises Price Target to $670

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Iovance Biotherapeutics (IOVA – Research Report) and Madrigal Pha...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Iovance Biotherapeutics (IOVA) and Madrigal Pharmaceuticals (MDGL)

Evercore ISI analyst Liisa Bayko notes that Akero Therapeutics' (AKRO) stock is trading up over 100% after the company released "impressive" data i...

Madrigal dip on Akero data a buying opportunity, says Evercore ISI

Madrigal Pharmaceuticals (MDGL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Liisa Bayko...

Positive Outlook for Madrigal Pharmaceuticals Driven by Rezdiffra's Potential and Market Opportunity

89bio stock rallies 40% amid data for rival MASH drug

Piper Sandler reiterated an Overweight rating and $336 price target on Madrigal Pharmaceuticals (MDGL) after Akero Therapeutics (AKRO) announced "p...

Akero cirrhosis data positive for Madrigal, says Piper Sandler

Madrigal Pharmaceuticals (MDGL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yasmeen Rah...

Promising Outlook for Madrigal Pharmaceuticals Amidst Positive Data and Market Potential

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Hold rating on Madrigal Pharmaceuticals (MDGL – Research Report)...

B.Riley Financial Keeps Their Hold Rating on Madrigal Pharmaceuticals (MDGL)

Akero: Reversal Of Cirrhosis With EFX Is A 'First' In F4 MASH Patients

MoneyShow's Best Investment Ideas For 2025: Part 7

89bio's Pegozafermin Is Now Gaining Momentum

AKRO

ARCC

ASML

ASMLF

ETNB

HESM

IMMR

IOVA

MARA

MDGL

NONOF

TOST

VKTX

VLGEA

Health Care

Press Releases

Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)

Comments

Madrigal Pharmaceuticals

Noticias

Últimas noticias sobre Madrigal Pharmaceuticals (NASDAQ:MDGL) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL